Pipelines & Products

Hyaluronic Acid (HA) is a type of acidic glycosaminoglycan that is widely found in the intercellular matrix of human tissues, the vitreous humor of the eye, joint synovial fluid, and other connective tissues. As a gel-like substance, it restricts the diffusion of water and other extracellular materials, thus controlling the mobility of subcutaneous fluids. Hyaluronidase （EC 3.2.1.35）, also known as HAase, is an endoglycosidase enzyme that breaks down hyaluronic acid. It hydrolyzes the β-1,4-glycosidic bonds in HA polymers, which enhance tissue permeability and fluid penetration. Clinically, hyaluronidase can be used as a drug permeation enhancer, anesthetic adjunct, or postoperative edema-relieving agents.

Ricefidase is a novel IgG-degrading enzyme derived from a non-human pathogenic strain of Streptococcus equi subspecies. It works through a unique and efficient mechanism to rapidly break down pathogenic “bad antibodies”，thus effectively alleviating the symptoms of related diseases. Its applications are broad, ranging from treating acute and severe autoimmune diseases to effectively eliminating pre-existing antibodies in gene therapy.
Ricefidase efficiently cleaves IgG into F(ab’)2 and Fc fragments, with its effects kicking in within just one hour after administration. This product has been independently developed by Bao Pharma and is patented globally. Ricefidase has completed Phase I clinical trials with positive results in both New Zealand and China, and Phase II/III clinical trials are currently underway.
Additionally, Ricefidase has received IND permission from the FDA for the treatment of a wide range of autoimmune diseases caused by pathological IgG. Extensive clinical trials have shown that Ricefidase is safe and well-tolerated, with rapid and complete degradation of IgG achieved as the dosage increases.

Chymotrypsin is a protease that rapidly breaks down proteins, liquefies pus, and necrotic tissue. It has been used in clinical practices for over 50 years and is widely applied across nearly 20 departments, including respiratory, surgical, otolaryngological, obstetric, pediatric, dental, ophthalmic, dermatological, gastrointestinal, and anorectal surgery.
Currently available domestic drugs are extracted from bovine or porcine pancreases, and there is a general safety concern about the medical risks associated with animal-derived products. Bao Pharma has pioneered to produce medicinal recombinant human chymotrypsin in a yeast expression system, distinguished from animal-derived alternatives. This method utilizes widely available and inexpensive raw materials to yield a pure and non-allergenic protein, ensuring safety and reliability. By developing animal-source-free and plasma-free biopharmaceuticals to replace those extracted from animal tissues, Bao Pharma is at the forefront of advancing the field of biochemically extracted drugs to a new level.

KJ015 is an anti-HER2 bispecific antibody independently designed by Bao Pharma, featured in common light chain technology. With high affinity for both epitopes, KJ015 can induce antigen clusters on the cell surface, demonstrating comprehensive superiority over monoclonal antibodies’ combination in the treatment of HER2-positive tumors. Preclinical validations have focused on gastric esophageal adenocarcinoma, including cholangiocarcinoma, gallbladder cancer, parotid cancer, endometrial cancer, ovarian cancer, and colorectal cancer, making its clinical performance in malignant tumors with high and moderate HER2 expression highly anticipated. Additionally, KJ015’s pharmacodynamic properties in HER2-positive breast cancer also show competitive advantages.
KJ015’s symmetric molecular design promises high stability, high expression levels, and a simple and cost-effective production process. When combined with our self-developed hyaluronidase, it can further enhance the clinical application advantages of subcutaneous administration, offering both safety and convenience, and exhibit strong market competitiveness.

Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced and secreted by the basophilic cells of the anterior pituitary gland. In males, it promotes the development of spermatogenic epithelium, the initiation of sperm production, and sperm maturation. In females, it stimulates follicular development and maturation, works together with luteinizing hormone to prompt mature follicles to secrete estrogen and ovulate, and is involved in the formation of normal menstrual cycles. For patients undergoing superovulation or assisted reproductive technologies, FSH can stimulate the development of multiple follicles.
SJ02 (FSH-CTP) is a long-acting form of FSH with modified glycosylation sites. It does not alter its biological activity but has a prolonged half-life, 2-3 times longer than that of FSH. Unlike conventional short-acting FSH, which requires daily injections for 10-14 days, SJ02 can replace a week's worth of these injections with just a single dose. This not only ensures the effectiveness and safety of treatment but also improves the patient experience, reduces the workload on medical institutions, and lowers healthcare costs.
The production process of SJ02 is complex, with significant technical barriers in expression and purification, and there was a technological gap in this field in China. Bao Pharma's independently developed SJ02, the first domestic recombinant FSH-CTP product, has successfully broken the monopoly of foreign products, enhancing China's international competitiveness in biopharmaceutical technology. It also reduces the medication costs and alleviates patients’ physical and psychological distress.

Human chorionic gonadotropin (hCG) is a glycoprotein hormone secreted by the placenta that stimulates gonadal activity. In females, it helps mature the follicles and triggers ovulation, and also converts the ruptured follicle into the corpus luteum, prompting it to secrete progesterone. In males, it promotes seminiferous tubule function and the activity of interstitial cells in the testes, increasing the production of androgens, facilitating testicular descent, and promoting sperm production.
hCG is commonly used in assisted reproductive procedures to accelerate follicular maturation and induce ovulation. When used for superovulation in assisted reproduction, it requires high-dose injections to mimic the pre-ovulatory luteinizing hormone surge, thereby speeding up follicular maturation and triggering ovulation. In addition to its use in assisted reproduction, hCG is also used to treat conditions such as prepubertal cryptorchidism, male hypogonadotropic hypogonadism, female luteal phase deficiency, and functional uterine bleeding.